CGEM
Cullinan Therapeutics (CGEM) Reports Q4 Loss of $0.77 Per Share, Flat Year-Over-Year
Cullinan Therapeutics posts $0.73 per share loss in Q4 2025, matching year-ago results as the pre-revenue biotech maintains clinical development…
Cullinan Therapeutics posts $0.73 per share loss in Q4 2025, matching year-ago results as the pre-revenue biotech maintains clinical development…